Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Tom Wei-Wu Chen^1,2,3

¹Department of Oncology and Center of Excellence for Sarcoma, National Taiwan University Hospital, Taipei, Taiwan.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|March 19, 2026

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Age-related differences in outcomes and tumor characteristics of ultra-rare sarcomas: A Nation-wide Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026

Same author

Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.

Therapeutic advances in medical oncology·2025

Same author

Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.

Cancer medicine·2024

Same author

Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.

Cancer medicine·2023

Same author

The proteomic landscape of soft tissue sarcomas.

Nature communications·2023

Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

See all related articles

Eribulin showed promise in epithelioid hemangioendothelioma (EHE) but requires further study in angiosarcoma. Histology-specific approaches are crucial for developing drugs for rare sarcomas.

Area of Science:

Oncology
Medical Research

Background:

Angiosarcoma and epithelioid hemangioendothelioma (EHE) are rare vascular tumors.
Limited treatment options exist for advanced cases of these sarcomas.

Purpose of the Study:

To evaluate the efficacy of eribulin in patients with angiosarcoma and EHE.
To explore histology-specific responses to eribulin treatment.

Main Methods:

Two prospective international clinical trials were conducted.
Patients with angiosarcoma and EHE received eribulin treatment.

Main Results:

Encouraging activity of eribulin was observed in epithelioid hemangioendothelioma.
The role of eribulin in angiosarcoma may require further subgroup analysis for optimal patient selection.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Related Experiment Videos

Last Updated: Mar 21, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Conclusions:

Eribulin demonstrates potential in treating EHE.
Histology-specific interpretation and tailored drug development strategies are vital for rare sarcoma subtypes like angiosarcoma.